Soros Fund Management LLC Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)

Soros Fund Management LLC bought a new stake in Upstream Bio, Inc. (NASDAQ:UPB) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 46,350 shares of the company’s stock, valued at approximately $762,000. Soros Fund Management LLC owned 0.09% of Upstream Bio as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. US Bancorp DE acquired a new stake in Upstream Bio during the 4th quarter worth approximately $27,000. Legal & General Group Plc purchased a new stake in Upstream Bio in the fourth quarter valued at $28,000. Summit Investment Advisors Inc. acquired a new stake in shares of Upstream Bio in the 4th quarter valued at about $30,000. Tower Research Capital LLC TRC acquired a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $47,000. Finally, Corebridge Financial Inc. acquired a new stake in Upstream Bio during the 4th quarter worth $142,000.

Upstream Bio Price Performance

NASDAQ UPB opened at $8.98 on Wednesday. The business’s 50-day moving average price is $7.90 and its 200 day moving average price is $14.37. Upstream Bio, Inc. has a 52-week low of $5.14 and a 52-week high of $29.46.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.